Mergers & Acquisitions ·
XOMA Royalty Corporation announced that the acquisition of XOMA Royalty Holdings Corporation by Ligand Pharmaceuticals…
XOMAXOMA Royalty Corp
XOMA Royalty Corporation announced that the acquisition of XOMA Royalty Holdings Corporation by Ligand Pharmaceuticals Incorporated is expected to close on or about July 14, 2026. Additionally, the company delivered notices to redeem all outstanding shares of its 8.625% Series A and 8.375% Series B Cumulative Perpetual Preferred Stock on July 14, 2026, at a price of $25.00 per share or depositary share plus accrued and unpaid dividends. XOMA Royalty Corporation operates in the biotechnology royalty industry, managing a portfolio of royalty interests in pharmaceutical products.